Market Overview

Protalix Says Reviewing Partnering, Other Alternatives

Related PLX
Stocks Hitting 52-Week Lows
Protalix Biotherapeutics Reports New Data on ELELYSO, Oral GCD Will Be Presented at European Working Group on Gaucher Disease

Protalix BioTherapeutics, Inc. (NYSE: PLX) confirms, in response to inquiries received this morning and a report appearing in the Israeli press, that the company has engaged Citigroup to assist it in reviewing a broad array of product partnering, technology sharing and other strategic alternatives. There is no assurance that Protalix will undertake any such strategic alternative.

Protalix will not comment further on this initiative unless future events would make doing so appropriate.

Posted-In: News


Related Articles (PLX)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters